1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B.CO
Novo Nordisk A/SDK flagNASDAQ Copenhagen
314.90
DKK
+3.35
- -
1.40TMarket Cap
Novo Nordisk A/S
NOVO-B.CO
(NASDAQ Copenhagen)

Recent

price

314.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.47
11.73
14.23
15.6
16.94
20.99
22.09
22.58
23.11
25.7
27.2
30.65
39.06
51.81
65.2
69.58
73.76
Revenue per Share
2.48
3.02
3.91
4.7
5.05
6.78
7.5
7.71
7.98
8.2
9.03
10.4
12.26
18.67
22.67
23.06
27.44
Basic EPS, GAAP
2.72
3.19
3.39
4.16
5.22
6.2
7.91
6.57
6.66
7.49
6.4
10.36
14.16
15.62
15.64
6.53
6.95
Free Cash Flow per Basic Share
0.76
1.01
1.41
1.81
2.26
2.51
4.71
3.81
3.94
4.09
4.31
4.68
5.58
7.09
9.91
11.65
11.66
Dividend per Share
6.32
6.67
7.21
7.78
7.97
9.21
9.21
10
11.14
12.28
13.76
15.77
17.89
23.49
32.53
44.07
46.55
Book Value per Share
6.12
6.36
7.14
7.64
7.42
8.72
8.41
9.4
9.65
10.9
9.14
6
7.18
10.3
7.33
14.41
16.46
Tangible Book Value per Share
5,805
5,654
5,483
5,359
5,244
5,142
5,060
4,946
4,839
4,749
4,668
4,594
4,531
4,483
4,454
4,442
4,444
Basic Weighted Avg Shares
60,776
66,346
78,026
83,572
88,806
107,927
111,780
111,696
111,831
122,021
126,946
140,800
176,954
232,261
290,403
309,064
327,800
Sales/Revenue/Turnover
31.08
33.72
37.77
37.68
38.84
45.81
43.33
43.84
42.25
43.01
42.64
41.65
42.28
44.16
44.19
41.3
45.3
Operating Margin (%)
2,467
2,737
2,693
2,799
3,435
2,959
3,193
3,182
3,925
5,661
5,753
6,025
7,362
9,413
19,107
21,982
21,688
Depreciation Expense
14,403
17,097
21,432
25,184
26,481
34,860
37,925
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
121,957
Net Income, GAAP
21.23
22.02
22.94
22.6
22.33
19.83
20.66
21.67
18.87
19.78
20.69
19.17
19.6
20.05
20.6
21.53
21.66
Effective Tax Rate (%)
23.7
25.77
27.47
30.13
29.82
32.3
33.93
34.14
34.54
31.92
33.19
33.92
31.38
36.03
34.78
33.14
37.2
Profit Margin (%)
18,817
18,812
18,525
17,833
12,604
14,267
12,330
13,024
4,903
3,473
-4,464
-13,921
-12,746
-30,009
-55,826
-43,208
-47,841
Working Capital
504
502
- -
- -
- -
- -
- -
- -
- -
3,009
2,897
12,961
24,318
20,528
89,674
118,941
119,172
LT Debt
36,965
37,448
40,632
42,569
40,294
46,969
45,269
49,815
51,839
57,593
63,325
70,746
83,486
106,561
143,486
194,047
203,065
Total Equity
38.02
43.86
56.42
56.57
60.67
83.38
76.18
73.07
68.92
69.94
60.88
53.92
56.09
64.64
51.89
34.23
36.44
Return on Invested Capital (%)
39.27
44.69
54.64
61.56
62.8
76.79
79.73
77.94
73.3
66.78
61.8
55.25
54.22
70.35
53.84
36.82
41.04
Return on Capital (%)
40.15
45.97
55.49
61.99
63.43
78.21
80.73
79.36
74.74
69.44
68.77
69.87
72.34
89.82
80.73
60.14
70.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
12,034
12,017
27,210
LT Borrowings
89,180
111,705
119,172
LT Finance Leases
- -
7,236
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,441
4,443
4,438
Market Capitalization
1,531,678
1,445,179
1,026,193

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
181,883
172,453
177,317
Cash, Cash Equivalents & STI
32,583
26,962
21,626
Accounts Receivable, Net
75,421
70,856
82,565
Inventories
47,504
49,623
51,352
Total Current Liabilities
234,358
215,661
225,158
Payables & Accruals
46,239
161,523
150,202
ST Debt
12,034
12,017
27,210
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.88%
25.45%
35.24%
Free Cash Flow
4.46%
8.88%
-58.38%
Net Income, GAAP
12.21%
20.48%
1.43%
Sales/Revenue/Turnover
11.61%
19.86%
6.43%
Total Cash Common Dividend
17.67%
21.26%
17.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65,349
68,060
71,311
85,683
290,403
2025
78,087
76,857
74,976
79,144
309,064
2026
96,823
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.7
4.5
6.13
6.35
22.67
2025
6.54
5.96
- -
6.05
23.06
2026
10.93
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.4
- -
3.5
- -
9.91
2025
7.95
-0.04
- -
- -
11.65
2026
7.95
- -
- -
- -
- -
Similar Companies
AbbVie Inc. (ABBV.BA)
MIRA Pharmaceuticals, Inc. (MIRA)
AbbVie Inc. (4AB.DE)
Ono Pharmaceutical Co., Ltd. (OPHLF)
Bayer AG (BAYN.SW)
Fangzhou Inc. (6086.HK)
Business
Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, founded in 1923, specializing in the research, development, manufacture, and marketing of pharmaceutical products primarily focused on diabetes care, obesity, rare diseases, and biopharmaceuticals. Its main product portfolio includes diabetes and obesity care products such as insulin and GLP-1 receptor agonists (including the Ozempic and Wegovy brands); insulin delivery systems; and treatments for hemophilia, growth hormone therapy, and hormone replacement therapy. The company operates across more than 180 countries, with key markets in North America, Europe, and Asia. Recent major developments include the acquisition of cardiovascular disease-focused Cardior Pharmaceuticals and the Montreal-based biotech Inversago Pharma to expand its metabolic disorder pipeline, along with a $2.2 billion collaboration with US biotech Septerna to develop oral small molecule therapies for obesity, type 2 diabetes, and cardio-metabolic disorders. Novo Nordisk is advancing next-generation obesity drugs such as CagriSema, currently in phase 3 trials, which has demonstrated significant weight loss in clinical studies, as well as oral and injectable amycretin candidates targeting dual hormone pathways for enhanced weight management. The company has also received US and EU approvals for Alhemo® (Concizumab), for hemophilia treatment, and continues to invest substantially in R&D and production capacity to meet growing global demand, aiming to reinforce its leadership in diabetes, obesity, and emerging cardio-metabolic therapies while expanding into chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH). Novo Nordisk’s strategic focus includes sustaining market share in GLP-1 segments, launching innovative treatments, and pursuing acquisitions and partnerships to strengthen its therapeutic areas and product offerings globally.